Chest
Original Research: COPDThe COPD Assessment Test: Can It Discriminate Across COPD Subpopulations?
Section snippets
Study Population, Design, and Assessments
Canadian Cohort Obstructive Lung Disease (CanCOLD) is a prospective cohort study designed to track > 1,500 subjects (male and female subjects aged ≥ 40 years) recruited by using a random sampling frame from nine urban and suburban areas in Canada and based on the International Burden of Obstructive Lung Disease Initiative.6, 7 The cohort comprises two balanced COPD subpopulations (GOLD 1 and GOLD ≥ 2) and two age- and sex-matched non-COPD subjects (ever-smoker for those at risk and never smoker
Demographic and Subject Characteristics
A total of 716 subjects with COPD who completed the baseline visit in the CanCOLD study were included in this analysis. Table 1 summarizes the participants’ sociodemographic and clinical characteristics. Forty percent of subjects were women, and approximately one-quarter of the individuals were < 60 years of age and in the group aged ≥ 75 years. More than one-half of the study population was classified as having mild airflow obstruction (GOLD 1). Almost three-quarters of the subjects had not
Discussion
In the present observational study, we confirmed that the CAT is valid according to specific characteristics in a random-sampled, population-based cohort of individuals with COPD. We tested the CAT in individuals with undiagnosed COPD and in those with mild disease and found that CAT scores are increased (ie, a worsened health status) in subjects with worsening airflow obstruction and in those with exacerbations. Similar to symptom scores and reports in other medical and respiratory diseases,
Conclusions
The present study provides cross-sectional and longitudinal data on the CAT from a well-characterized, population-based sample of subjects with COPD. Our characterization of CAT scores according to women, those with mild airflow obstruction vs moderate/severe obstruction, and those with exacerbations beyond GOLD classification established that the questionnaire is a valid measurement tool to assess health status in a population-based cohort that reflects COPD patients at large. These results
Acknowledgments
Author contributions: J. B. takes responsibility for the content of the manuscript, including the data and analysis. N. G. and J. B. contributed to the conception and implementation of the study, acquisition and analysis of the data, and writing and revision of the manuscript. L. P., A. B., W. C. T., S. D. A., K. R. C., J. M. F., P. H., D. D. M., F. M., D. E. O., B. L. W., and D. S. contributed to the acquisition of the data and the revision of the article. P. Z. L. contributed to the analysis
References (16)
- et al.
Improving the process and outcome of care in COPD: development of a standardised assessment tool
Prim Care Respir J
(2009) - et al.
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study
Lancet
(2007) - et al.
The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes
J Clin Epidemiol
(2010) - et al.
Psychometric evaluation of the COPD assessment test: data from the BREATHE study in the Middle East and North Africa region
Respir Med
(2012) - et al.
Development of the Japanese version of the COPD Assessment Test
Respir Investig
(2012) - Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis M, and Prevention...
- et al.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary
Am J Respir Crit Care Med
(2013) - et al.
Development and first validation of the COPD Assessment Test
Eur Respir J
(2009)
Cited by (12)
The COPD assessment test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients
2023, PulmonologyCitation Excerpt :The score for each item ranges from 0 to 5 and the total score (0–40) provides a simple and quantified measure of health-related quality of life, with higher scores indicating poorer health status.4 There is a body of evidence concerning the reliability of CAT as predictor of diagnosis,5,6 disease exacerbation,6-8 and mortality.9 On the other hand, a simple measure of dyspnea, such as the modified Medical Research Council (mMRC) scale is also considered appropriate for the assessment of the symptoms,10 since it relates to health status,11 and may predict mortality risk of COPD patients.12
Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting
2019, Journal of the American Pharmacists AssociationCitation Excerpt :Further evidence for this may be inferred from the relatively high average age of the study population, the high proportion of smokers, and the CAT score results: 90% of participants had scores ≥10. Previous studies have demonstrated associations between increasing CAT score and airflow limitation or COPD severity53-56; in addition, despite the nonspecific nature of the symptoms described by the CAT, significantly higher scores have been reported in individuals with airflow limitation characteristic of COPD than individuals without, and it has been suggested that the test may prove useful for case finding.57,58 Data from 2 studies showed that the majority of individuals with airflow limitation have CAT scores > 758; more than 90% of the participants in the present study met this criterion.
A systematic literature review of the humanistic burden of copd
2021, International Journal of COPDRecent Advances in the Physiological Assessment of Dyspneic Patients with Mild COPD
2021, COPD: Journal of Chronic Obstructive Pulmonary Disease
FUNDING/SUPPORT: The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is currently funded by the Canadian Respiratory Research Network; industry partners are AstraZeneca Canada Ltd., Boehringer Ingelheim Canada Ltd., GlaxoSmithKline Canada Ltd., and Novartis. Researchers at RI-MUHC Montreal and Icapture Centre Vancouver lead the project. Previous funding partners were the CIHR (CIHR/Rx&D Collaborative Research Program Operating Grants, 93326) and the Respiratory Health Network of the FRSQ; industry partners were Almirall, Merck, Nycomed, Pfizer Canada Ltd., and Theratechnologies.